KDKerry Dierberg

Kerry Dierberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kerry Dierberg has a total of 239 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prophylaxie post-exposition contre le virus Ebola : arguments en faveur d’un élargissement du rôle des anticorps monoclonaux dans un contexte d’accès limité

    by Julien Potet, Ismael Adjaho, Kerry Dierberg, Armand Sprecher, Rebecca Marie Coulborn

    Alors que la maladie à virus Ebola (MVE) reste une menace majeure, des progrès récents ont permis l’homologation de plusieurs produits médicaux, en particulier le vaccin rVSVΔG-ZEBOV-GP (Ervebo) et deux traitements par anticorps monoclonaux, mAb114 (Ebanga) et REGN-EB3 (Inmazeb). Leur utilisation en prophylaxie post-exposition (PPE) reste cependant peu documentée. Notre revue narrative de la littérature et des lignes directrices proposées par des organisations en réponse aux épidémies d’Ebola vise à évaluer le potentiel du vaccin rVSVΔG-ZEBOV-GP et des anticorps monoclonaux mAb114 et REGN-EB3 pour une PPE suite à une exposition à haut risque d’infection. Très peu d’études ont été menées spécifiquement pour déterminer l’efficacité des vaccins ou des anticorps monoclonaux en PPE. Les données chez l’animal et chez l’homme suggèrent que le vaccin rVSVΔG-ZEBOV-GP n’offre qu’une protection limitée en PPE, bien qu’il puisse réduire la sévérité de la MVE si elle survient. Aucune des 34 personnes ayant reçu le vaccin dans le cadre de la PPE à ce jour n’a développé de MVE. Une étude rétrospective cas-témoins suggère une efficacité de seulement 16 % contre la survenue de la MVE lorsque le vaccin est administré pendant une période compatible avec la PPE. En revanche, les anticorps monoclonaux mAb114 et REGN-EB3, en raison de leur action immédiate par immunisation passive, semblent conférer une protection plus élevée contre la survenue de la MVE après une exposition à haut risque, avec une survie à 100 % en modèle animal, bien que les données cliniques humaines restent rares avec seulement 23 cas d’utilisation recensés en PPE et aucune survenue de MVE. L’accès aux anticorps monoclonaux pour les membres de la communauté ayant fait l’objet d’une exposition à haut risque devrait être assuré, tout en optimisant les critères d’évaluation du risque. Des recherches supplémentaires, notamment sur l’interaction entre vaccination et administration d’anticorps, sont essentielles pour déterminer les stratégies de PPE les plus efficaces. Enfin, un stock d’urgence d’anticorps monoclonaux et une amélioration du suivi des contacts sont indispensables pour renforcer la réponse aux épidémies. Malgré les limites des données actuelles, les anticorps monoclonaux devraient être envisagés comme option prioritaire en PPE pour les personnes à haut risque.

  • Top Cited Papers

    Remdesivir for the Treatment of Covid-19 — Final Report

    by John H. Beigel, Kay M. Tomashek, Lori E. Dodd, Aneesh K. Mehta, Barry S. Zingman, Andre C. Kalil, Elizabeth Hohmann, Helen Y. Chu, Annie Luetkemeyer, Susan Kline, et al.

    Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.)


  • Open Access

    Marburg virus disease: A summary for clinicians

    by Mark G. Kortepeter, Kerry Dierberg, Erica S. Shenoy, Theodore J. Cieslak


  • Open Access

    Strengthening provision of essential medicines to women and children in post-Ebola Sierra Leone

    by Rebecca Kahn, Sheriff Bangura, Katrina Hann, Ameet Salvi, Joseph Gassimu, Alpha Kabba, Annelies W Mesman, Kerry L Dierberg, Regan H Marsh


  • Open Access

    A comprehensive district-level laboratory intervention after the Ebola epidemic in Sierra Leone

    by Annelies W. Mesman, Musa Bangura, Sahr M. Kanawa, Joseph S. Gassimu, Kerry L. Dierberg, Mohamed M. Sheku, J. Daniel Orozco, Regan H. Marsh

    Background: The 2014–2016 Ebola outbreak exposed the poor laboratory systems in Sierra Leone. Immense needs were recognised across all areas, from facilities, diagnostic capacity, supplies, trained personnel to quality assurance mechanisms.Objective: We aimed to describe the first year of a comprehensive intervention, which started in 2015, in a public hospital’s general laboratory serving a population of over 500 000 in a rural district.Methods: The intervention focused on (1) supporting local authorities and healthcare workers in policy implementation and developing procedures to enhance access to services, (2) addressing gaps by investing in infrastructure, supplies, and equipment, (3) development of quality assurance mechanisms via mentorship, bench-side training, and the introduction of quality control and information systems. All work was performed alongside counterparts from the Ministry of Health and Sanitation.Results: We observed a strong increase in patient visits and inpatient and outpatient testing volumes. Novel techniques and procedures were taken up well by staff, leading to improved and expanded service and safety, laying foundations for further improvements.Conclusion: This comprehensive approach was successful and the results suggest an increase in trust from patients and healthcare workers.


  • Open Access

    Minimally Symptomatic Infection in an Ebola ‘Hotspot’: A Cross-Sectional Serosurvey

    by Eugene T. Richardson, J. Daniel Kelly, Mohamed Bailor Barrie, Annelies W. Mesman, Sahr Karku, Komba Quiwa, Regan H. Marsh, Songor Koedoyoma, Fodei Daboh, Kathryn P. Barron, et al.

    Evidence for minimally symptomatic Ebola virus (EBOV) infection is limited. During the 2013–16 outbreak in West Africa, it was not considered epidemiologically relevant to published models or projections of intervention effects. In order to improve our understanding of the transmission dynamics of EBOV in humans, we investigated the occurrence of minimally symptomatic EBOV infection in quarantined contacts of reported Ebola virus disease cases in a recognized ‘hotspot.’ We conducted a cross-sectional serosurvey in Sukudu, Kono District, Sierra Leone, from October 2015 to January 2016. A blood sample was collected from 187 study participants, 132 negative controls (individuals with a low likelihood of previous exposure to Ebola virus), and 30 positive controls (Ebola virus disease survivors). IgG responses to Ebola glycoprotein and nucleoprotein were measured using Alpha Diagnostic International ELISA kits with plasma diluted at 1:200. Optical density was read at 450 nm (subtracting OD at 630nm to normalize well background) on a ChroMate 4300 microplate reader. A cutoff of 4.7 U/mL for the anti-GP ELISA yielded 96.7% sensitivity and 97.7% specificity in distinguishing positive and negative controls. We identified 14 seropositive individuals not known to have had Ebola virus disease. Two of the 14 seropositive individuals reported only fever during quarantine while the remaining 12 denied any signs or symptoms during quarantine. By using ELISA to measure Zaire Ebola virus antibody concentrations, we identified a significant number of individuals with previously undetected EBOV infection in a ‘hotspot’ village in Sierra Leone, approximately one year after the village outbreak. The findings provide further evidence that Ebola, like many other viral infections, presents with a spectrum of clinical manifestations, including minimally symptomatic infection. These data also suggest that a significant portion of Ebola transmission events may have gone undetected during the outbreak. Further studies are needed to understand the potential risk of transmission and clinical sequelae in individuals with previously undetected EBOV infection. With over 28,000 reported cases, the 2013–16 West African Ebola virus disease epidemic is the largest and longest on record. This study provides further evidence that Ebola, like other viruses, causes a spectrum of clinical manifestations that may include minimally symptomatic infection. The findings also suggest that many episodes of human-to-human transmission of Ebola virus in West Africa may have gone undetected in the recent outbreak. This has implications for the definition of Ebola virus disease survivorship, delineation of transmission chains, and future vaccine studies.


  • Open Access

    Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone

    by Corrado Cancedda, Sheila M. Davis, Kerry L. Dierberg, Jonathan Lascher, J. Daniel Kelly, Mohammed Bailor Barrie, Alimamy Philip Koroma, Peter George, Adikali Alpha Kamara, Ronald Marsh, et al.

    An epidemic of Ebola virus disease (EVD) beginning in 2013 has claimed an estimated 11 310 lives in West Africa. As the EVD epidemic subsides, it is important for all who participated in the emergency Ebola response to reflect on strengths and weaknesses of the response. Such reflections should take into account perspectives not usually included in peer-reviewed publications and after-action reports, including those from the public sector, nongovernmental organizations (NGOs), survivors of Ebola, and Ebola-affected households and communities. In this article, we first describe how the international NGO Partners In Health (PIH) partnered with the Government of Sierra Leone and Wellbody Alliance (a local NGO) to respond to the EVD epidemic in 4 of the country's most Ebola-affected districts. We then describe how, in the aftermath of the epidemic, PIH is partnering with the public sector to strengthen the health system and resume delivery of regular health services. PIH's experience in Sierra Leone is one of multiple partnerships with different stakeholders. It is also one of rapid deployment of expatriate clinicians and logistics personnel in health facilities largely deprived of health professionals, medical supplies, and physical infrastructure required to deliver health services effectively and safely. Lessons learned by PIH and its partners in Sierra Leone can contribute to the ongoing discussion within the international community on how to ensure emergency preparedness and build resilient health systems in settings without either.


  • Open Access

    Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India

    by Kerry L. Dierberg, Kunchok Dorjee, Fulvio Salvo, Wendy A. Cronin, J’BElle Boddy, Daniela Cirillo, Tsetan Sadutshang, Richard E. Chaisson

    The incidence of tuberculosis (TB) among Tibetan refugees in India is 431 cases/100,000 persons, compared with 181 cases/100,000 persons overall in India in 2010. More than half of TB cases in these refugees occur among students, monks, and nuns in congregate settings. We sought to increase TB case detection rates for this population through active case finding and rapid molecular diagnostics. We screened 27,714 persons for symptoms of TB and tested 3,830 symptomatic persons by using an algorithm incorporating chest radiography, sputum smear microscopy, culture, and a rapid diagnostic test; 96 (2.5%) cases of TB were detected (prevalence 346 cases/100,000 persons). Of these cases, 5% were multidrug-resistant TB. Use of the rapid diagnostic test and active case finding enabled rapid detection of undiagnosed TB cases in congregate living settings, which would not have otherwise been identified. The burden of TB in the Tibetan exile population in India is extremely high and requires urgent attention.


  • Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study

    by John G Mattia, Mathew J Vandy, Joyce C Chang, Devin E Platt, Kerry Dierberg, Daniel G Bausch, Tim Brooks, Sampha Conteh, Ian Crozier, Robert A Fowler, et al.


  • Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India

    by Kathleen Stevens, Trinley Palmo, Tsering Wangchuk, Sunil Solomon, Kerry Dierberg, Christopher J. Hoffmann

    Untreated chronic hepatitis B can lead to liver failure and/or liver cancer. These complications can be avoided through prevention with vaccination or treatment of disease. To inform health policy for the Tibetan community in India, we conducted study of hepatitis B prevalence and treatment needs.We conducted a cross-sectional study over three months of 2013. Households were randomly selected for participation via a satellite map; one boarding school and one residential monastery were also included. Participants were asked questions and a whole blood sample was collected for HBsAg assay. Participants with a positive HBsAg result were tested for hepatitis B e antigen, ALT, and AST. Participants with a negative HBsAg result were tested for anti-hepatitis B core antibodies.We recruited 2,769 participants; of which 247 (8.9%) were positive for HBsAg. Participants more likely to have a positive HBsAg result were those born in Tibet (12.4%) and aged 30 to 59 years old. Of those with a positive HBsAg result, 60.7% were positive for hepatitis B e antigen 7% of whom fit into a likely treatment-needed category; the others fit into management categories requiring repeat ALT testing with or without liver fibrosis assessment. Among participants negative for HBsAg, 52.9% from household sampling had anti-HBc antibodies.We identified a high endemicity of chronic hepatitis B in a Tibetan community in India. Resource appropriate approaches are needed for managing chronic hepatitis B in settings such as this one. This article is protected by copyright. All rights reserved.